Literature DB >> 11547718

Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding.

C Villanueva1, J Miñana, J Ortiz, A Gallego, G Soriano, X Torras, S Sáinz, J Boadas, X Cussó, C Guarner, J Balanzó.   

Abstract

BACKGROUND: After an episode of acute bleeding from esophageal varices, patients are at high risk for recurrent bleeding and death. We compared two treatments to prevent recurrent bleeding--endoscopic ligation and combined medical therapy with nadolol and isosorbide mononitrate.
METHODS: We randomly assigned 144 patients with cirrhosis who were hospitalized with esophageal variceal bleeding to receive treatment with endoscopic ligation (72 patients) or the combined medical therapy (72 patients). Sessions of ligation were repeated every two to three weeks until the varices were eradicated. The initial dose of nadolol was 80 mg orally once daily, with adjustment according to the resting heart rate; isosorbide mononitrate was given in increasing doses, beginning at 20 mg once a day at bed time and rising over the course of one week to 40 mg orally twice a day, unless side effects occurred. The primary end points were recurrent bleeding, complications, and death.
RESULTS: The median follow-up period was 21 months. A total of 35 patients in the ligation group and 24 in the medication group had recurrent bleeding. The probability of recurrence was lower in the medication group, both for all episodes related to portal hypertension (P=0.04) and for recurrent variceal bleeding (P=0.04). There were major complications in nine patients treated with ligation (seven had bleeding esophageal ulcers and two had aspiration pneumonia) and two treated with medication (both had bradycardia and dyspnea) (P=0.05). Thirty patients in the ligation group died, as did 23 patients in the medication group (P=0.52). The probability of recurrent bleeding was lower for patients with a hemodynamic response to therapy, defined as a decrease in the hepatic venous pressure gradient of more than 20 percent from the base-line value or to less than 12 mm Hg (18 percent, vs. 54 percent in patients with no hemodynamic response at one year; P<0.001), and the probability of survival was higher (94 percent vs. 78 percent at one year, P=0.02).
CONCLUSIONS: Combined therapy with nadolol and isosorbide mononitrate is more effective than endoscopic ligation for the prevention of recurrent bleeding and is associated with a lower rate of major complications. A hemodynamic response to treatment is associated with a better long-term prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11547718     DOI: 10.1056/NEJMoa003223

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  40 in total

1.  Management of esophageal varices: an update from Digestive Disease Week and American Association for the Study of Liver Diseases 2003.

Authors:  Samer Gawrieh; Kia Saeian
Journal:  Curr Gastroenterol Rep       Date:  2004-06

2.  Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients.

Authors:  Shiv K Sarin; Manav Wadhawan; Rajesh Gupta; Hansa Shahi
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 3.  Management of portal hypertension.

Authors:  D N Samonakis; C K Triantos; U Thalheimer; D W Patch; A K Burroughs
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

Review 4.  Portal hypertension--old problem, new therapeutic solutions.

Authors:  Markus Peck-Radosavljevic
Journal:  Wien Med Wochenschr       Date:  2006-07

Review 5.  Hepatic venous pressure gradient: worth another look?

Authors:  Sameer Parikh
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

6.  Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis.

Authors:  Lan Li; Chaohui Yu; Youming Li
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

7.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 8.  Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence.

Authors:  U Thalheimer; M Mela; D Patch; A K Burroughs
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding.

Authors:  Hui Xue; Meng Zhang; Jack Xq Pang; Fei Yan; Ying-Chao Li; Liang-Shan Lv; Jia Yuan; Muna Palikhe; Wei-Zhi Li; Zhi-Lun Wang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

10.  EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study.

Authors:  Jason Y Huang; Jason B Samarasena; Takeshi Tsujino; John Lee; Ke-Qin Hu; Christine E McLaren; Wen-Pin Chen; Kenneth J Chang
Journal:  Gastrointest Endosc       Date:  2016-09-29       Impact factor: 9.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.